Quick Answer
Hepion Pharmaceuticals, Inc. reported Diluted EPS of $0.88 per share (loss) for fiscal year 2025.
Hepion Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.88 | +99.2% |
| 2024 | -$107.35 | +82.6% |
| 2023 | -$616.07 | -5077.1% |
| 2022 | -$11.90 | -2431.9% |
| 2021 | -$0.47 | +77.6% |
| 2020 | -$2.10 | -51.1% |
| 2018 | -$1.39 | +42.3% |
| 2017 | -$2.41 | -282.5% |
| 2016 | -$0.63 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.04 | +99.9% | +55.6% |
| June 30, 2025 | -$0.09 | +99.7% | +95.8% |
| March 31, 2025 | -$2.15 | +92.4% | +94.1% |
| September 30, 2024 | -$36.21 | -1221.5% | -6.5% |
| June 30, 2024 | -$34.00 | -823.9% | -20.9% |
| March 31, 2024 | -$28.13 | -708.3% | -926.6% |
| September 30, 2023 | -$2.74 | -22.3% | +25.5% |
| June 30, 2023 | -$3.68 | +29.5% | -5.7% |
- Hepion Pharmaceuticals, Inc. showed an increase of +99.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, Hepion Pharmaceuticals, Inc.’s diluted eps has declined by 39.7% (from $0.63 per share (loss) to $0.88 per share (loss)).
- The most recent figure is from Hepion Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: